Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab

• Main Authors: Marie‐Emilie Willemin (Author), Shun Xin Wang Lin (Author), Loeckie De Zwart (Author), Liviawati S. Wu (Author), Xin Miao (Author), Raluca Verona (Author), Arnob Banerjee (Author), Baolian Liu (Author), Rachel Kobos (Author), Ming Qi (Author), Daniele Ouellet (Author), Jenna D. Goldberg (Author), Suzette Girgis (Author)
• Format: Book
• Published: Wiley, 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Cytokine release syndrome (CRS) was associated with teclistamab treatment in the phase I/II MajesTEC‐1 study. Cytokines, especially interleukin (IL)‐6, are known suppressors of cytochrome P450 (CYP) enzymes' activity. A physiologically based pharmacokinetic model evaluated the impact o...